The Dollar Rally Comes To An End

Hello MarketClub members everywhere. The stock market is taking a breather today and the dollars five-day advanced has ended as traders have turned cautious before Fed Chair Janet Yellen discusses the state of the economy later today. Everyone will be listening for clues about when and how much the Federal Reserve will raise interest rates.

MarketClub's Mid-day Market Report

Gold (FOREX:XAUUSDO) has slipped 0.3% to $1,229.20 an ounce. It's down 2.1 percent for the week, after four straight weeks of gains. The U.S.Dollar Index (NYBOT:DX.M16.E) is down .3% as well, ending a five day rally that saw it top $102.19.

Key levels to watch next week: Continue reading "The Dollar Rally Comes To An End"

7 Essential Tips To Succeed With Cannabis Stocks

Analysis originally distributed on February 22, 2017 By: Michael Vodicka of Cannabis Stock Trades

Interest in cannabis stocks is spiking in 2017.

This trend isn’t just on display with higher trading volume. It is also validated by the most powerful search engine in the world: Google.

When I typed marijuana stocks into Google Trends this chart below came up.

As you can see, search volume for marijuana stocks spiked to an all-time high during the election and once again early this year.

Marijuana Stocks Google Search Results
Chart courtesy of Google Trends

This is a bullish signal for cannabis stocks.

It tells me additional capital will be flowing into the sector from investors eager to profit from legal cannabis. Continue reading "7 Essential Tips To Succeed With Cannabis Stocks"

Dow Races Above 21,000 After President Trump's Speech

Hello MarketClub members everywhere. The Dow has crossed 21,000 for the first time, the dollar has jumped the most in six weeks and Treasuries fell as investors grew increasingly confident global economic growth is accelerating, clearing the path for higher interest rates.

MarketClub's Mid-day Market Report

Big banks led gains among stocks, with The Goldman Sachs Group Inc. (NYSE:GS) and JPMorgan Chase & Co. (NYSE:JPM) trading at all-time highs as the odds for a rate hike in two weeks swelled past 65 percent and President Donald Trump's address to Congress did little to alter views that his administration will seek pro-growth policies.

Key levels to watch next week: Continue reading "Dow Races Above 21,000 After President Trump's Speech"

Why Doesn't The Bond Market Trust The Fed?

George Yacik - INO.com Contributor - Fed & Interest Rates


The minutes of the Federal Reserve’s January 31-February 1 meeting released last week said we can expect another interest rate increase “fairly soon,” which many people think means at the March 14-15 meeting, just two weeks away. But the bond market doesn’t seem to be buying it. Why not?

According to the minutes, “many participants expressed the view that it might be appropriate to raise the federal funds rate again fairly soon if incoming information on the labor market and inflation was in line with or stronger than their current expectations or if the risks of overshooting the committee’s maximum-employment and inflation objectives increased.”

At her Congressional testimony a week earlier, Fed Chair Janet Yellen was even more hawkish, warning that “waiting too long to remove accommodation would be unwise, potentially requiring the FOMC to eventually raise rates rapidly, which could risk disrupting financial markets and pushing the economy into recession.” That doesn’t sound like someone who’s willing to wait until May, the Fed’s next monetary policy meeting after March (there’s no meeting in April). Continue reading "Why Doesn't The Bond Market Trust The Fed?"

Preview Issue #11: J&J $30B Acquisition, Humana/Aetna Blocked and Allergan Sued

INO Health & Biotech Stock Guide

Preview Issue #11 - February 28, 2017

BIOTECH, HEALTH & PHARMA NEWS

Johnson & Johnson and McKesson make a big splash in merger and acquisition activity, courts block Humana/Aetna merger and Allergan and Endo sued by FTC. The healthcare cohort has witnessed several key events in the face of a political backdrop that’s put the entire industry on edge. The overall healthcare umbrella has become sensitive to any tweet from President Trump as he vows to bring down drug prices. As he pursues his crusade against drug pricing, much of these threats may have already been priced-in as seen in many healthcare-related stocks (i.e. McKesson, CVS, ABBV and AGN) that have seen sharp and sustained sell-offs that coincide with the 2017 presidential campaign cycle.

WHAT'S NEXT

Continue reading "Preview Issue #11: J&J $30B Acquisition, Humana/Aetna Blocked and Allergan Sued"